反应详情

A mixture of (R)-1′-[2-(1-butyryloxy-ethyl)-pyrimidin4-yl]-6-chloro-spiro[chroman-2,4′-piperidin]4-one (prepared according to the method of Example 78, Step B, 270 mg, 0.61 mmol) and lithium hydroxide hydrate (80 mg, 1.83 mmol) in a 3:1:1 mixture of tetrahydrofuran/methanol/water (5 mL) was stirred at room temperature for 1.5 h. The organic solvents were evaporated and the residue was extracted with chloroform (4×). The combined organic extracts were dried over sodium sulfate, filtered, evaporated, and purified by flash column chromatography (ethyl acetate) to give 41 mg (18%) of the title compound as a reddish foam. 1H NMR (CDCl3, 300 MHz) δ 8.19 (d, 1H), 7.82 (d, 1H), 7.44 (dd, 1H), 6.96 (d, 1H), 6.40 (d, 1H), 4.65 (q, 1H), 4.20 (app s, 2H), 3.42-3.32 (c, 2H), 2.73 (s, 2H), 2.14 (d, 2H), 1.67 (td, 2H), 1.48 (d, 3H); MS (APCI) 374, 376 (MH+); [α]D+12.6 (c 0.5, MeOH).

1. customprepared
2. customThe organic solvents were evaporated
3. extractionthe residue was extracted with chloroform (4×)
4. dry with materialThe combined organic extracts were dried over sodium sulfate
5. filtrationfiltered
6. customevaporated
7. custompurified by flash column chromatography (ethyl acetate)